MedBridgeNZ Insights: Your Guide to Cross-Border Healthcare in China

Home > Blog > Advanced Therapies & Technology Written by the MedBridgeNZ Patient Care Team | Updated September 2026 Key Takeaways Ask for the exact trial registration number. A hospital name, treatment label or brochure is not enough to identify a study. Check whether the sponsor, cell product, investigator, hospital campus and recruitment status match the public record. A registry entry establishes traceability. Current recruitment, international access and individual eligib

Home > Blog > Advanced Therapies & Technology A search for an experimental Parkinson’s treatment can uncover a more basic question: is the diagnosis definitely Parkinson’s disease, or does the medical record describe parkinsonism without confirming its cause? This is more than a difference in terminology. Parkinsonism describes a pattern of movement signs. Parkinson’s disease is one possible cause—and the cause matters before an invasive treatment is considered. Atypical neur

Home > Blog > Advanced Therapies & Technology For a family exploring medical care overseas, the first question is often about treatment: Is a particular therapy available? Is a clinical trial accepting international patients? Would travelling to China open up another option? Those questions matter, but a specialist usually needs to answer a more basic one first: is there enough reliable information to review the case properly? A remote Parkinson’s second opinion in China can

Home > Blog > Advanced Therapies & Technology Families often reach this question after finding a Parkinson’s study online and wondering whether it is worth contacting the hospital—or even planning a trip to China. The possibility may feel encouraging, but a public listing rarely explains how the study handles enquiries from people who live overseas. Some international patients may be assessed for Parkinson’s clinical trials in China. Acceptance, however, depends on the protoc

Home > Blog > Advanced Therapies & Technology By MedBridgeNZ | Last updated: 30 August 2026 | Evidence reviewed: 30 August 2026 For families reading a trial listing, the published age range can look like a clear doorway: “My relative has Parkinson’s disease and falls within that range—does this mean they qualify?” Unfortunately, no public listing can answer that question on its own. Age is only the most visible part of Parkinson’s stem cell trial eligibility in China. Before

Home > Blog > Travel & Hospital Navigation A gut microbiome test in China may be available as a stand-alone service or as an optional addition to a wider health-screening visit. The test analyses microbial DNA in a submitted stool sample and may describe which microorganisms were detected, their relative abundance and selected diversity measures. The important question is not simply whether the test is available. It is whether the method, report and follow-up arrangements can

Home > Blog > Travel & Hospital Navigation First Things First: Does an "Abnormal" Result Mean I'm Sick? Not necessarily. Receiving a flagged result can be unsettling, especially if you are about to leave China or are waiting on pending reports. However, an abnormal result on its own is not a diagnosis—it simply means a specific value fell outside the standard reference range and requires a closer look. Your next steps might be as simple as a repeat blood test, or they may inv

Home > Blog > Travel & Hospital Navigation At MedBridgeNZ, one of the most common questions we hear from clients planning a trip to China is: "Can I just add a gene mapping test to my health check?" The short answer is yes, but it’s rarely a one-size-fits-all situation. Before you book, here is a quick summary of what you actually need to know: Key Takeaways Genetic testing is generally an optional add-on, not a standard part of a routine health-check package. Germline testin

Home > Blog > Travel & Hospital Navigation Planning health checkups for several relatives during one Shanghai visit involves more than reserving a block of appointments. A hospital may place family members within the same date window, but each person still needs an individual registration, screening plan, preparation instructions, payment record and report. The practical goal is not to make every appointment identical. It is to create one coordinated family schedule while pre

Home > Blog > Travel & Hospital Navigation International visitors may be able to arrange a Pap smear in Shanghai together with an HPV test through a standalone gynecology appointment. Before choosing a date, however, it is important to confirm the hospital's consultation policy, exact test names, current charges, preparation instructions, report language and reporting arrangements. Screening recommendations vary by country and individual circumstances. The receiving clinician

Home > Blog > Travel & Hospital Navigation Key Takeaways Not every health check-up in China requires fasting. The correct preparation depends on the exact blood tests, imaging, endoscopy, sedation, and sample-based tests confirmed for your appointment. Follow the hospital's final written instructions for each person. A package name, a general website checklist, or another family member's instructions may not match your test list. Do not stop or change regular medication witho

Home > Blog > Travel & Hospital Navigation Key Takeaways “Basic,” “standard,” “VIP,” and “executive” are hospital-defined package labels, not universal medical standards. A practical comparison starts with baseline screening, then considers age, personal and family history, previous results, and screening goals. New, persistent, or concerning symptoms require an appropriate clinical assessment rather than a larger preventive screening package. Broader testing may produce more

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Evidence last checked: August 2026 Key Takeaways Investigational Status: CD7-directed therapies for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are not commercially approved medications in China. They remain investigational under hospital-sponsored or clinical trial protocols. Overcoming Biological Hurdles: Investigational platforms have explored natural selection, intracellu

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: August 2026 Key Takeaways Conditional BCMA Approvals: China’s National Medical Products Administration (NMPA) has conditionally approved several autologous BCMA-directed CAR-T products for specified adults with relapsed or refractory multiple myeloma after prior treatment. Alternative Antigen Targeting: For patients experiencing disease progression after BCMA-targeted therapy, investigational GPRC5D CAR

Home > Blog > Travel & Hospital Navigation Key Takeaways Mechanisms of Failure: Relapse following cellular immunotherapy typically occurs through either antigen-negative escape (loss or mutation of the targeted protein) or antigen-positive persistence failure (T-cell exhaustion or early clearance). Target Re-Profiling Is Essential: Establishing next-step feasibility requires a repeat biopsy with quantitative flow cytometry or immunohistochemistry to confirm whether the origin

Home > Blog > Travel & Hospital Navigation Key Takeaways Initial remote acceptance for CAR-T therapy is based on historical medical records and does not constitute final approval for apheresis. Institutional protocols require continuous reassessment of disease progression, blood counts, and infection status prior to cell collection. Recent chemotherapy or bridging therapies often necessitate strict washout periods to ensure sufficient lymphocyte viability. The clinical feasib

Home > Blog > Travel & Hospital Navigation Key Takeaways China operates a dual-track healthcare system where high-volume clinical expertise is concentrated in public Grade 3A hospitals, while private/international hospitals focus on administrative accessibility and premium logistical support. The fundamental CAR-T products and cellular technologies remain consistent across hospital types; the primary differences lie in bilingual support, consultation formats, and payment work

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 12 August 2026 For international patients, the CAR-T treatment timeline in China is usually measured in weeks, not days. It may include medical-record review, travel, reassessment, leukapheresis, cell manufacturing, lymphodepletion, infusion, monitoring and clearance to return home. Manufacturing time is only one part of the journey. This guide explains the stages that can change the total stay—and what

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 11 August 2026 International patients researching commercial CAR-T vs clinical trials in China are often presented with two apparently simple choices: pay for a commercially available product or try to enter a clinical trial. The real distinction is more complex. An approved product is approved only for specified indications and still requires hospital assessment. A clinical trial offers access under a

Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Last updated: 10 August 2026 If you have recently received chemotherapy and are considering CAR-T, the CAR-T washout period cannot be reduced to one universal number. The relevant interval depends on the treatment, the disease, whether T cells have already been collected, the intended CAR-T product or protocol, blood-count recovery, infection status, organ function and the receiving centre's requirements. Evidence sc